Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Nasopharyngitis, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Tested positive for COVID19 on Saturday; Tested positive for COVID19 on Saturday; Chills; sweats; cold; allergy symptoms; Booster; This is a spontaneous report from a contactable consumer (patient) or other non hcp. A 49-year-old male patient received third dose of bnt162b2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: F73527, Expiration Date: was not reported), via an unspecified route of administration, administered in left arm, on 02Nov2021 at 12:45 (at the age of 49 year), as dose 3 (booster), single for COVID-19 immunization. Medical history included hypertension from an unknown date and unknown if ongoing, affective disorder (mood disorder) from an unknown date and unknown if ongoing, depression from an unknown date and unknown if ongoing, sleep apnoea syndrome from an unknown date and unknown if ongoing, mild asthma from an unknown date and unknown if ongoing, seasonal allergy from an unknown date and unknown if ongoing. Concomitant medications included lisinopril (LISINOPRIL) taken for an unspecified indication, start and stop date were not reported; atenolol (ATENOLOL) taken for an unspecified indication, start and stop date were not reported; lamotrigine (LAMOTRIGINE) taken for an unspecified indication, start and stop date were not reported; bupropion hydrochloride (WELLBUTRIN) taken for an unspecified indication, start and stop date were not reported; colecalciferol (D3) taken for an unspecified indication, start and stop date were not reported. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: EM9809, Expiration Date: was not reported), via an unspecified route of administration, administered in left arm, on 09Feb2021 at 13:00 (at the age of 48 year), as dose 1, single for COVID-19 immunization and the patient received second dose of bnt162b2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: EN6205, Expiration Date: was not reported), via an unspecified route of administration, administered in left arm, on 02Mar2021 at 13:00 (at the age of 48 year), as dose 2, single for COVID-19 immunization. The patient received other vaccine in four weeks was not reported. The patient received other medication in two weeks were Lisinopril, Atenolol, Lamotrigine, Wellbutrin, D3. Prior vaccination, the patient was not diagnosed with COVID-19. Post vaccination, the patient was tested for COVID-19. The patient had no known allergies. On 03Nov2021 at 05:00, the patient experienced chills, sweats, cold and allergy symptoms. The adverse event was resulted in emergency room (department or urgent case) visit. The patient stated, she was tested positive for COVID-19 (Nasal Swab, RT-PCR) on 06Nov2021 and though she knows you cannot get the virus as a direct result, she wanted to make you aware in case of any cross-contamination issues may affect others. The patient was not received treatment for the adverse events. The outcome of the COVID-19 positive was unknown. The outcome of the chills, sweats, cold and allergy symptoms was recovering.